More Articles

Bionomics of biosimilars – India’s next big cash cow? Biosimilars/General | Posted 02/03/2010

As reported by Ms Nayantara Som in BioSpectrumIndia of 13 January 2010, biosimilars are said to be the next big cash cow for India. According to her, however, players have many knots to untangle be...

FDA accepts Teva’s biosimilar filgrastim BLA, Amgen not Biosimilars/News | Posted 26/02/2010

The US FDA has accepted Teva‘s application to sell a biosimilar version of Amgen's Neupogen (filgrastim), although the biotech giant is working to block the move in court.XM02, a granulocyte colony...

Originator/generic competition: who's the 'bad guy'? Pharma News | Posted 26/02/2010

As reported in Scrip News on 28 January 2010 by Xavier Buffet Delmas and Laura Morelli of Hogan & Hartson MNP, Paris, intellectual property rights are key elements of the fierce competition bet...

Obama refuses to put US healthcare reform on the shelf Policies & Legislation | Posted 26/02/2010

As reported by Scrip, US President Mr Barack Obama made clear that he is continuing to push for sweeping changes in the US healthcare system that would extend coverage of tens of millions of Americ...

Developing biobetters through evergreening is ‘high value’ Reports | Posted 24/02/2010

As reported by Subita Srimal in Mehta Perspectives on 6 January 2010, investment in biologics-based medicine is gaining momentum as these drugs offer targeted therapy and often safer treatment opti...

Mehta BioPharma Outlook 2010: Emerging markets not as attractive as they seem Reports | Posted 24/02/2010

As reported by Scrip, the emerging markets may not be as lucrative as they are being made out to be, at least in the short-term, and are expected to attain critical size only by around 2014, accord...

Abbott: Non-responding RA patients with anti-infliximab antibodies may switch to less immunogenic anti-TNF Biosimilars/Research | Posted 22/02/2010

In the race for biosimilar/biobetter monoclonal antibodies (MAbs), it is interesting to compare originator MAbs, e.g. mouse-human chimeric infliximab (Remicade) of Johnson & Johnson’s Centocor...

FDA: Counterfeit orlistat has risky sibutramine amount Generics/News | Posted 22/02/2010

As reported by Scrip, the US FDA has re-iterated its concerns about a counterfeit version of GlaxoSmithKline's Alli (orlistat), which contains varying degrees of sibutramine rather than the correct...